Anavex Life Sciences Stock News

Anavex Life Sciences Corp (NASDAQ: AVXL ) announced topline results from its Phase 1 trial of ANAVEX3-71 in development for neurodegenerative diseases, including Frontotemporal Dementia (FTD). ANAVEX3-71 was well tolerated in all cohorts receiving single doses of … Full story available on Benzinga.com

Anavex Life Sciences Corp (NASDAQ: AVXL) announced topline results from its Phase 1 trial of ANAVEX3-71 in development for neurodegenerative diseases, including Frontotemporal Dementia (FTD). ANAVE

NEW YORK, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therap

NEW YORK, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ: AVXL ), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer''s disease, Parkinson''s disease, Rett syndrome and other central nervous system (CNS) disorders, today announced that Walter E Kaufmann, M.D. has been promoted to Chief Scientific Officer and Edward R Hammond, M.D., M.P.H., PhD, has been appointed Chief Medical Officer, effective immediately. Before joining Anavex over three years ago, Dr. Kaufmann was the Director of the Center for Translational Research at the Greenwood Genetic Center, where he also held the Ravenel Boykin Curry Chair in Genetic Therapeutics. He holds adjunct appointments at Emory University School of Medicine, where he is an Adjunct Professor of Human Genetics. Dr. Kaufmann is also a Simons Investigator at the Massachusetts Institute of Technology''s Simons Center for the Social Brain.

Anti-Amyloid Drugs: The Failure Of Success

Investors need to pay close attention to Anavex (AVXL) stock based on the movements in the options market lately.

Investors need to pay close attention to Anavex (AVXL) stock based on the movements in the options market lately.

Biopharma stocks eked out modest gains in the week ending Dec. 23, with regulatory decisions, clinical readouts and COVID-19 treatment and vaccine developments dictating sentiment. The week's news w

During the last session, Anavex Life Sciences Corp. (NASDAQ:AVXL)s traded shares were 3.16 million, with the beta value of the company hitting 0.61. At the end of the trading day, the stocks price was $18.14, reflecting an intraday gain of 1.23% or $0.22. The 52-week high for the AVXL share is $31.50, that puts it Anavex Life Sciences Corp. (NASDAQ: AVXL) Fall -27.93% In Six Months, Heres What We Should Expect Now Read More »

Anavex Life Sciences Corp. (NASDAQ:AVXL) has received an average recommendation of Buy from the seven ratings firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1 year target price among brokerages that []

Opus Capital Group LLC grew its position in shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) by 57.1% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 16,500 shares of the biotechnology company’s stock after buying an additional 6,000 shares during the quarter. […]

Thursday, January 13, 2022 at 8:15 am Pacific Time / 11:15 am Eastern Time Thursday, January 13, 2022 at 8:15 am Pacific Time / 11:15 am Eastern Time

Royal Bank of Canada lifted its stake in Anavex Life Sciences Corp. (NASDAQ:AVXL) by 23.1% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 12,488 shares of the biotechnology companys stock after buying an additional 2,346 shares during the period. Royal Bank []

Absci (NASDAQ:ABSI) and Anavex Life Sciences (NASDAQ:AVXL) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, analyst recommendations, profitability, dividends and risk. Analyst Ratings This is a summary of current recommendations and price targets for Absci and []

Stem cell therapies are back in vogue, at least for this Miami-based biotechnology company.